Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs

• by Ashik Anil Mathew, Arulkumaran Rithvik, Mahaboobkhan Rasool

• July 9, 2026

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

• by Rachael A. Gordon, Sara S. McCoy

• July 1, 2026

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

• by Andrea Surnit

• July 6, 2026

• 3 min

Homocitrullinated Peptides Drive Pro-Inflammatory T Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

• by Sofya Ulanova, Jaspreet Kaur, Gabrielle Buckley, S. M. Mansour Haeryfar, Lisa Cameron, Ewa Cairns, Lillian Barra

• June 17, 2026